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THERE ARE SEVERAL NATURALLY occurring isoforms of growth hormone (GH) produced by two genes, one expressed in the pituitary, human growth hormone-N ("hGH-N" also known as "hGH-1"), and one expressed in the placenta, human growth hormone-variant ("hGH-V" also known as "hGH-2"). The major form of hGH-N is a 22-kDa protein consisting of 191 amino acids. A second form of hGH-N is produced by alternative splicing of the same gene; this results in deletion of a region corresponding to amino acids 32-46 of 22-kDa hGH to produce a 20-kDa protein (20-kDa hGH-N). Various other splice variants of hGH-N have been described previously (6) .
GH-V is synthesized and secreted by syncytiotrophoblasts during pregnancy and although the exact function of this variant is still to be elucidated, numerous studies (17, 19) suggest that hGH-V is important in the regulation of fetal growth and development. In support of an effect on fetal growth, low levels of maternal 22-kDa hGH-V have been reported in pregnancies complicated by intrauterine growth retardation (30) . hGH-V is not regulated by GH-releasing hormone and is secreted tonically from the placenta throughout gestation. Due to the structural similarity with hGH-N, hGH-V is supposed to convey similar somatogenic effects but reduced lactogenic activity (21) . Igout et al. (21) compared the somatogenic and lactogenic activity of the recombinant 22-kDa hGH-V isoform produced in Escherichia coli and compared it with the 22-kDa form of hGH-N. The two variants exert a similar somatogenic effect on rabbit and rat cells but differed in regards to their lactogenic activity in the rat (21) .
The most abundant placental GH (22-kDa hGH-V) binds to the growth hormone receptor (GHR) with equal affinity as hGH-N, and maternal plasma IGF-I levels parallel those of hGH-V concentrations during pregnancy (9, 10, 29) . Maternal serum levels of placental GH increase throughout pregnancy from 7 wk of gestation until term and gradually replace the pulsatile pituitary GH secretion (11) .
Approximately 10% of the pituitary hGH-N transcripts use an alternative splice acceptor site resulting in a 20-kDa hGH-N isoform. Both 20-kDa and 22-kDa hGH-N have similar metabolic activities relating to growth promotion and body fat reduction (33, 37) and bind with similar affinity to the human GHR (40, 43) . In adult patients with GH deficiency, the 20-kDa hGH-N exhibits metabolic effects similar to those of the 22-kDa hGH-N (20) . Human 20-kDa hGH-N also binds to lactogenic receptors and has been shown to exhibit prolactin receptor (PRLR)-mediated activity in vitro (35) . Although most studies report similar metabolic activities between the 22-kDa and 20-kDa hGH-N, it has been shown that the antidiuretic and diabetogenic actions of the 20-kDa hGH-N are weaker than those of 22-kDa hGH-N (37, 38) .
The expression of the placental 20-kDa hGH-V seems to vary among different full-term normal and abnormal placentas, as the transcript encoding the 20-kDa hGH-V is found in some but not all placentas. It has since been suggested that this variation may in part explain the previous unsuccessful attempts at detecting this transcript (7) . The 20-kDa hGH-V variant, the result of a 45-bp deletion caused by the use of an alternative acceptor site within exon 3, was described by Boguszewski et al. (7) . To date, the biological properties of the 20-kDa hGH-V isoform have not been characterized in vivo, mainly due to the lack of sufficient amounts of recombinant hormone. However, following the work of Solomon et al. (36) , large-scale preparation and in vitro characterization of biologically active 20-kDa GH-V has now only recently allowed the production of quantities suitable for in vivo experimentation. In vitro experiments have demonstrated that this 20-kDa hGH-V as well as 22-kDa hGH-V has no lactogenic activity in Baf/3 LP cells stably transfected with human PRLR (36) . The 22-kDa hGH-V is proposed as a likely candidate to mediate the insulin resistance of normal pregnancy (3, 4) . A study in nonpregnant transgenic mice revealed that the 22-kDa hGH-V caused insulin resistance at levels above those seen in the human third trimester due to increased expression of the P85 regulatory unit of phospatidylinositol 3-kinase, triggering severe insulin resistance in skeletal muscle (4, 5) .
The use of GH therapy in the treatment of children with short stature and in adult GH deficiency is widely established. However, despite the well-known effects of GH on improving body composition, lipid profiles, cardiovascular function, and bone density, there are some issues with GH therapy as it exists at present related to fluid retention and altered insulin sensitivity. Previous work on the 20-kDa GH-V has been performed in vitro, and no studies to date have characterized the biological action of the 20-kDa GH-V in vivo. The aim of the present study in the rat was therefore to investigate for the first time the comparative biological effects of the 20-kDa GH-V against the native 22-kDa GH-N.
MATERIALS AND METHODS
Animal model. Male Wistar rats were purchased from a colony maintained by the Vernon Jansen Unit at the University of Auckland at a weaning age (22 days). Animals were acquired at this age (i.e., 3-4 wk before investigative age) to allow time for acclimatization and familiarization of handling with the investigating personnel. Animals were housed in a dedicated facility using standard rat cages and normal 12:12-h light-dark cycles and were given unlimited access to food and water. At weaning, animals (n ϭ 18 per group) were weight matched to be fed with standard rat chow (Diet 2018; Harlan Teklad, Oxon, UK) or a commercial high-fat (HF) diet (D12492, 60% kcal as fat; Research Diets, NJ, USA). The animals were monitored daily from weaning until the completion of the studies. All animal work was done under protocols approved by the Animal Ethics Committee at the University of Auckland.
Treatment protocol. At 7-8 wk of age, rats (n ϭ 36) were weight matched and fat matched [using dual energy X-ray absorptiometry (DEXA) scanning] within the chow and HF diet groups and assigned to one of three treatment groups (n ϭ 6 per group) to receive either vehicle (sterile physiological saline; 0.9%), hGH-N (5 g⅐g Ϫ1 ⅐day
Ϫ1
), or recombinant 20-kDa hGH-V (5 g⅐g Ϫ1 ⅐day
). hGH-N (Genotropin; Pfizer) was reconstituted using physiological saline (0.9%). The 20-kDa hGH-V (Protein Laboratories Rehovot, Israel and Michael Waters, University of Queensland) was produced in E. coli as a single, nonglycosylated, polypeptide chain containing 177 amino acids with a molecular mass of 20,498 Da and purified as previously described (36) . The 20-kDa hGH-V was reconstituted in 20 mM Na 2CO3 and mixed by gentle inversion. Injections (100-l vol) were administered by subcutaneous injection given twice daily at 0800 and 1700. Animals were treated for 7 days and euthanized on the morning of day 8 following a final saline or hGH-N/20-kDa hGH-V injection.
Animals were weighed between 8 -9 AM every day for the duration of the experiment. Total body adiposity was quantified by DEXA (QDR 4500; Hologic, Waltham, MA). Food intake was measured on a daily basis for the duration of the trial. Relative food intake per rat (grams consumed per grams body wt per day) was calculated using the amount of food given to and the amount of food left uneaten by each pair in each group. Water consumption was calculated daily by weighing water bottles at the same time on each day of the study. Body lengths (nose-to-anus and nose-to-tail) were assessed at the time of DEXA scanning using standard measurement techniques.
Tissue and plasma measurements. Measurements of body length, body weight, organ weights (liver, spleen, kidney, adrenals, and heart), and fat pad weight (retroperitoneal) were taken. Trunk blood was collected into heparinized vacutainers for endocrine and biochemistry analysis. Blood samples were analyzed for insulin, C peptide, glucose, free fatty acids (FFAs), leptin, IGF-I, glycerol, triglycerides, creatinine, and urea.
Plasma insulin was measured by rat-specific ELISA (20-1145-01; Mercodia). Plasma C peptide was measured by rat-specific RIA (RCP-21K; Linco). Plasma IGF-I was measured using a rat specific EIA (DSL-10-2900; DSL). Glucose, FFAs, triglycerides, glycerol, creatinine, and urea were measured by in-house biochemistry analyzer (Roche-Hitachi Model 902 autoanalyzer). Rat leptin in plasma was measured using a specific rat leptin ELISA (EZRL-83K; Linco).
Microsomal membrane binding preparations. Ligand binding studies were performed using a well-established ovine hepatic membrane system (8) . The use of either 125 I-labeled recombinant bovine GH (rbGH) or 125 I-labeled ovine prolactin (oPRL) as labeled ligand reflects pure somatogenic or lactogenic activity, respectively, while the use of 125 I-hGH reflects a mixture of both somatogenic and lactogenic activity. Microsomal membrane preparations (MMPs) were prepared as previously described (8), and receptor assays were performed as previously validated for the rat liver (35) . In brief, radiolabeled rbGH, recombinant human GH-N (rhGH-N), or oPRL was obtained using a modified lactoperoxidase method to obtain a specific activity of 70 -90 Ci/g (39) . Membrane preparations (100 l) were incubated with ϳ40,000 cpm labeled hormone in a total incubation volume of 500 l. Nonspecific binding was determined by addition of 1,000 ng of unlabeled hormone. Equilibrium conditions were reached and specific binding was completely reversible by the addition of excess unlabeled hormone. The method of Lowry (28) was used to determine MMP protein concentrations. Specific binding was corrected for the protein content of the MMP.
MTT bioassay. Comparison of biopotencies of the 22-kDa hGH-N and the 20-kDa hGH-V were quantified in vitro utilizing a BaF/BO3 bioassay. Murine BaF/BO3 cells stably expressing the human GHR (BaF/BO3-B2B2 clone) were used as previously described by Rowland et al. (31, 32) with an MTT formazan dye endpoint. Samples were assayed in triplicate.
Statistical analysis. All statistics were performed using StatView statistical software (SAS Institute, Cary, NC). Data were tested for normality and analyzed using two-way factorial ANOVA with posthoc Bonferroni comparison with GH treatment and diet as factors. Body growth data were analyzed by repeated measures ANOVA. All data are shown as mean Ϯ SE unless otherwise stated. Significance was accepted at the P Ͻ 0.05 level.
RESULTS

Pretreatment.
Animals fed the HF diet had significantly increased total fat mass compared with chow fed animals before the start of treatment as assessed by DEXA scanning (chow: 14.9 Ϯ 0.6% and HF: 22 Ϯ 0.7%; P Ͻ 0.0001). At the onset of treatment, there were no significant differences in total body fat mass or absolute body weight between any of the treatment groups within diet.
Body weights and length. Body weight gain was significantly increased in 22-kDa hGH-N-treated and 20-kDa hGH-V-treated animals compared with saline-treated controls (Fig.  1, A-C) . Animals treated with the 20-kDa hGH-V showed an intermediary body weight gain between that of saline and 22-kDa hGH-N-treated animals with weight gain in 22-kDa hGH-N animals being significantly greater than that of animals treated with the 20-kDa hGH-V. Total body weight gain was increased overall in HF fed animals (Fig. 1B) . However, animals fed the HF diet showed a diminished weight gain response during 22-kDa hGH-N and 20-kDa hGH-V treatment compared with saline-treated controls as reflected in a significant diet ϫ treatment interaction.
Nose-to-anus lengths were significantly increased in animals treated with 22-kDa hGH-N compared with saline controls (Table 1) . Nose-to-anus length in 20-kDa hGH-V-treated animals was intermediary between the saline and 22-kDa hGH-N treatment groups and was not significantly different from either saline or 22-kDa hGH-N-treated animals. Nose-to-tail lengths were significantly increased in 22-kDa hGH-N-treated animals compared with saline-treated controls but were not significantly different from those of 20-kDa hGH-V-treated animals. There was a trend toward an increased nose-to-tail length in 20-kDa hGH-V-treated animals compared with saline controls.
Fat mass. Total fat mass was assessed by whole body DEXA scan. Total body fat mass was increased in all HF fed animals ( Fig. 2A) and was significantly decreased in all 22-kDa hGH-N-treated and 20-kDa hGH-V-treated animals compared with saline-treated controls. There was no difference in the total adipose mass between 22-kDa hGH-N-treated and 20-kDa hGH-V-treated animals on the HF diet, indicating similar efficacy in reducing fat mass between the two treatments. As with the total body adipose tissue, the fat-to-lean ratio was significantly in all HF fed animals ( Fig. 2B ) and was significantly decreased in all 22-kDa hGH-N-treated and 20-kDa hGH-V-treated animals compared with saline-treated controls. There was no difference in the fat-to-lean ratios between 22-kDa hGH-N-treated and 20-kDa hGH-V-treated animals, indicating similar efficacy in mediating changes in body composition. A significant diet ϫ treatment interaction indicated that both 22-kDa hGH-N and 20-kDa hGH-V treatments were more efficacious in improving body composition in animals fed the HF diet compared with chow fed controls.
Total caloric intake was slightly but significantly increased in saline-treated animals on the HF diet (data not shown). There was no difference in caloric intake between 22-kDa hGH-N-treated and 20-kDa hGH-V-treated animals. Water intake was slightly but significantly increased in 22-kDa hGH-N-treated animals over the length of the trial but was not different between saline and 20-kDa hGH-V-treated animals (data not shown).
Tissue weights. In addition to whole body adiposity as assessed by DEXA scanning, retroperitoneal fat pads were excised and weighed. Relative fat pad weights (weight expressed as a percentage of total body weight) were significantly increased in all HF fed animals ( Table 1) . Fat pad weights were significantly decreased in 22-kDa hGH-N-treated and 20-kDa hGH-V-treated animals compared with saline-treated animals. There were no significant differences in fat pad weight between 22-kDa hGH-N-treated and 20-kDa hGH-V-treated animals. Relative liver weight was increased in HF fed animals, but there were no significant differences in relative liver weight between any of the GH treatment groups. Relative spleen weights were significantly increased in the 22-kDa hGH-Ntreated animals, and there was a trend toward increased spleen weights in 20-kDa hGH-V-treated animals (P ϭ 0.0522). HF feeding had no effect on relative spleen weight (P ϭ 0.71).
Plasma measurements. Fasting plasma insulin concentrations were not different between any of the treatment groups fed the chow diet (Fig. 3A) . Plasma insulin concentrations were significantly increased in saline-treated animals fed the HF diet and further increased in 22-kDa hGH-N-treated animals fed the HF diet (Fig. 3A) . However, insulin concentration in animals fed the HF diet treated with the 20-kDa hGH-V were significantly lower than saline and 22-kDa hGH-N-treated animals on the HF diet and were not significantly different from animals fed the chow diet. This was reflected in a diet ϫ treatment interaction. Fasting plasma glucose concentrations were slightly but significantly decreased in 22-kDa hGH-N-treated groups (Table 2) , and there was a trend toward a decrease in fasting glucose in the 20-kDa hGH-V-treated animals. Fasting insulin-to-glucose ratios were significantly increased in HF fed animals ( Fig. 3B ) and were significantly increased in 22-kDa hGH-N-treated animals compared with saline-treated and 20-kDa hGH-V-treated animals. There were no significant differences in the insulin-to-glucose ratios between saline-treated animals and those treated with the 20-kDa hGH-V.
As observed with fasting insulin, plasma C-peptide concentrations (a marker of total insulin secretion) were not significantly different between any of the treatment groups fed the chow diet. Plasma C-peptide concentrations were significantly increased in saline-treated animals fed the HF diet (P Ͻ 0.05) and further significantly increased in 22-kDa hGH-N-treated animals fed the HF diet (P Ͻ 0.005, Fig. 3C ). However, C-peptide concentrations in animals fed the HF diet treated with the 20-kDa hGH-V were significantly lower than those of the 22-kDa hGH-N-treated animals and were not significantly different from animals fed the chow diet. This was reflected in a diet ϫ treatment interaction (P Ͻ 0.05). There were no differences in plasma IGF-I concentrations between animals fed either the chow or HF diet (P ϭ 0.55; Fig. 2D ). Plasma IGF-I concentrations were significantly increased in 22-kDa hGH-N animals compared with both saline-treated (P ϭ 0.0084) and 20-kDa hGH-V-treated animals (P ϭ 0.004). There were no significant differences in plasma IGF-I between saline-treated and 20-kDa hGH-V-treated animals (P ϭ 0.68). Fasting plasma leptin concentrations were significantly increased in all HF fed animals compared with chow fed (P Ͻ 0.0001; Fig. 2C ).
Plasma leptin concentrations were significantly decreased in HF fed animals treated with 22-kDa hGH-N or 20-kDa hGH-V compared with saline-treated animals on the HF diet (P Ͻ 0.005 and P Ͻ 0.01, respectively). There were no significant differences in plasma leptin between 22-kDa hGH-N-treated and 20-kDa hGH-V-treated animals (P ϭ 0.83). A diet ϫ treatment interaction indicated that both 20-kDa hGH-V and 22-kDa hGH-N reduced plasma leptin significantly more in HF fed animals than in chow fed animals (P Ͻ 0.05). Plasma leptin concentrations correlated positively with fat mass (r 2 ϭ 0.71). Plasma FFAs were significantly reduced in 20-kDa hGH-V animals compared with 22-kDa hGH-N-treated animals (P ϭ 0.02), and there was a trend toward a decrease in FFAs in 20-kDa hGH-V-treated animals compared with saline-treated animals (P ϭ 0.06). Plasma triglycerides were slightly but significantly decreased in HF fat fed animals and were significantly increased in 20-kDa hGH-V-treated animals compared with 22-kDa hGH-N-treated and saline-treated animals (P Ͻ 0.005 and P Ͻ 0.05, respectively). There were no significant differences in glycerol concentrations between any of the treatment groups. Fasting urea concentrations were significantly reduced in all HF fed animals (P Ͻ 0.0001). Plasma urea was significantly elevated in 20-kDa hGH-V-treated animals compared with saline-treated animals (P Ͻ 0.05). 22-kDa hGH-N treatment had no significant effect on plasma urea (P ϭ 0.78 compared with saline). Plasma creatinine concentrations were slightly but significantly decreased in HF fed animals and were increased in 20-kDa hGH-V-treated animals compared with saline (P Ͻ 0.05). There were no significant differences in plasma creatinine concentrations between 22-kDa hGH-Ntreated and 20-kDa hGH-V-treated animals (P ϭ 0.58). Blood hematocrits were slightly but significantly reduced in hGH-N- treated animals compared with saline-treated animals (P Ͻ 0.05). Hematocrits were not different between saline-treated and 20-kDa hGH-V-treated animals (P ϭ 0.21) and were not significantly different between 22-kDa hGH-N-treated and 20-kDa hGH-V-treated animals (P ϭ 0.43).
Competitive binding studies using MMPs. With the use of 125 I-rhGH-N, there are two distinctly different displacement curves; the steep curve of hGH displacement indicates strong lactogenic activity, while the shallow displacement of bovine (bGH) is indicative of weak lactogenic activity (Fig. 4A) . The 20-kDa hGH-V followed the shallow bGH-like displacement pattern indicative of weak lactogenic activity. In contrast, the 22-kDa hGH-V displayed a displacement curve similar to that of 22-kDa hGH-N indicative of increased lactogenic activity compared with the 20-kDa hGH-V. With the use of 125 I-oPRL, the 20-kDa hGH-V displayed no binding interactions indicative of an absence of lactogenic activity (Fig. 4B) . Assessment of somatogenic properties of the GH variants using 125 I-rbGH demonstrated that the displacement pattern of the binding curves was similar between the 20-kDa hGH-V and 22-kDa hGH-N (Fig. 4C) with the somatogenic potency of the 20-kDa-GH-V between that of rbGH and 22-kDa hGH-N.
MTT bioassay. Comparative potency curves generated using the MTT bioassay are presented in Fig. 4D . Based on the calculated EC 50 , the two batches of placental 20-kDa hGH-V had a potency of 0.51-fold (95% confidence limit 0.45-0.58) and 0.68-fold (95% confidence limit 0.53-0.88), respectively, to that of recombinant 22K hGH-N against the human GHR.
DISCUSSION
The present work is to our knowledge the first attempt to compare the properties of 20-kDa hGH-V to 22-kDa hGH-N as the former recombinant variant was not available in substantial amounts until the recent work of Solomon et al. (36) . The effects of both hormonal treatments on the body composition and antilipogenic activity as exemplified by changes in total body fat and leptin levels have demonstrated that both variants act with similar efficacy. In contrast, a striking difference between 22-kDa hGH-N and 20-kDa hGH-V was observed in all parameters (insulin, C-peptide, FFA, and TG levels) related to diabetogenic activity. The diabetogenic effects associated with 22-kDa hGH-N treatment are diminished in the 20-kDa hGH-V-treated animals, particularly in the presence of a post- natal obesogenic environment. Whereas 22-kDa hGH-N reduces insulin sensitivity as shown before by others (12, 13, 15, 24) , 20-kDa hGH-V not only has reduced diabetogenic activity but in fact is even mildly anti-diabetogenic compared with the controls in the presence of a postnatal high fat diet. Further, 20-kDa hGH-V is as lipolytic as 22-kDa hGH-N and did not display the same lactogenic effects as associated with 22-kDa hGH-N treatment. Body weight gain was intermediary between that of controls and 22-kDa hGH-N, with body weight gain blunted in all HF fed animals compared with chow fed GHtreated animals, a possible consequence of altered GH and insulin sensitivity in fat fed animals (14, 34, 42) . The reduced growth promotion by the 20-kDa hGH-V observed in vivo was paralleled by reduced potency of the 20-kDa hGH-V variant against the GHR compared with the 22-kDa hGH-N in the MTT in vitro assay.
Conventional GH treatment with 22-kDa GH-N has been shown to result in a higher than expected incidence of type 2 diabetes mellitus; a sixfold increase in type 2 diabetes has been reported in GH-treated children compared with age-matched untreated controls, which may reflect an acceleration of the disorder in predisposed individuals (12) . 20-kDa hGH-N has been shown to induce glucose intolerance (27) and impair insulin sensitivity (1), although some studies (38) have shown 20-kDa GH-N to be less potent than 22-kDa hGH-N at inducing insulin resistance in euglycemic clamp studies and in studies (22, 23) using GH-deficient dwarf rats. In humans, work by Hayakawa et al. (20) has shown that the 20-kDa hGH-N and 22-kDa hGH-N elicited similar insulin responses across treatment groups. The lipolytic and insulin-like activities of 22-kDa hGH-N and 22-kDa hGH-V have been shown to be similar in rat adipose tissue (18) . In the present trial, treatment with the 20-kDa hGH-V was suggestive of enhanced insulin sensitivity. Fasting plasma insulin concentrations were significantly increased in saline and 22-kDa hGH-N-treated animals fed the HF diet; an elevation not seen in the 20-kDa hGH-V treatment group where levels were similar to chow fed controls. This was paralleled by fasting C-peptide data where a HF diet increased C-peptide concentrations in saline and 22-kDa hGH-N-treated animals but had no effect in the 20-kDa hGH-V-treated animals. Of note, in the present trial it was not unexpected that fasting plasma glucose concentrations were not altered in any of the GH treatment groups given the dose and duration of treatment.
Early work (41) on 20-kDa hGH-N isolated from the pituitary and with a nonauthentic recombinant product gave quite different results to studies on an "authentic" version thus there are discrepancies in the literature describing the biological properties of 20-kDa hGH-N produced by different methods. Early studies (16, 25) on 20-kDa hGH-N purified from the pituitary indicated that the lipolysis activity of 20-kDa hGH-N was much weaker than 22-kDa hGH-N. This did not agree with results obtained using recombinant 20-kDa hGH-N with an authentic sequence (2, 37) . A 20-kDa hGH-N has also been shown to produce inhibition of lipoprotein lipase activity in adipose tissue and to stimulate lipolysis in adipocytes in a manner similar to 22-kDa hGH-N (37). The lipolytic activity of 20-kDa hGH-N may be higher than 22-kDa hGH-N in the presence of growth hormone binding protein (GHBP; Ref. 2) . In the present study, total body fat mass (as assessed by DEXA scanning and fat depot dissection) was significantly reduced in both 22-kDa hGH-N-treated and 20-kDa hGH-V-treated animals and 20-kDa hGH-V was as equally efficacious as hGH-N in adipose tissue reduction. The lipolytic effects were paralleled by the change in body composition (fat-to-lean) ratios where 20-kDa hGH-V and 22-kDa hGH-N were not signifi- cantly different in their ability to beneficially alter the fat-tolean ratios. Plasma leptin is well known to be reduced following 22-kDa hGH-N treatment and follows the pattern of fat reduction in treated animals; treatment with both 22-kDa hGH-N and 20-kDa hGH-V significantly reduced plasma leptin concentrations compared with saline-treated animals, and leptin levels were not different between those animals treated with either 20-kDa hGH-V or 22-kDa hGH-N. Surprisingly, plasma IGF-I levels were significantly increased with 22-kDa hGH-N treatment but were not significantly different in animals treated with the 20-kDa hGH-V compared with saline treated. This could reflect a transient increase in plasma IGF-I (corresponding to the initial rapid gain in body weight), which then reverses after the first 2 days of treatment. This may also be suggestive of IGF-I independent growth promoting activity of the 20-kDa hGH-V as per that shown by Wang et al. (44) for 22-kDa hGH-N, but further work is required to clarify this observation. It is also possible that 20-kDa hGH-V has a specific receptor dimerization mechanism as has been reported for 20-kDa hGH-N (45). In rodents, bGH binds only to the GHR, while hGH binds to both GHR and PRLR (26) . Data in the present study suggest that the placental 20-kDa acts like a pure somatogen compared with hGH-N and 22-kDa hGH-V. The placental 20-kDa hGH-V has very weak lactogenic activity and followed the reduced potency and the shallow bGH-like binding pattern in the hGH-N receptor assay and displayed no binding at all in the oPRL assay compared with hGH-N. The present study was not able to address possible changes in the GHBP in vivo. GHBP has the potential to modulate the proportion of free placental GH (29) and thus will be further investigated in independent trials.
In summary, 20-kDa hGH-V retains the lipolytic effects of 22-kDa hGH-N but displays altered efficacy as it relates to the development of unwanted side effects associated with altered insulin sensitivity and lactogenic binding affinities. Although the present trial did not investigate a direct in vivo comparison between 20-kDa hGH-V and 20-kDa hGH-N, the ligand binding data clearly suggest different lactogenic binding affinities between the two 20-kDa variants. A dose-response curve was beyond the scope of the present trial. However, in the absence of changes in circulating IGF-I levels and reduced body growth compared with the 22-kDa hGH-N, the establishment of a dose-response relationship between 20-kDa hGH-V and 22-kDa hGH-N is warranted to further investigate differences in growth and diabetogenic and lactogenic activity. The 20-kDa hGH-V may offer a possible alternative avenue for correction of growth disorders while ameliorating the well-cited side effects of long-term treatment with the native GH.
